Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

Daniele Armenia,D. Di Carlo,Andrea Calcagno,G. Vendemiati,Federica Forbici,Ada Bertoli,Giulia Berno,Stefania Carta,Fabio Continenza,Valentina Fedele,Rita Bellagamba,S. Cicalini,A. Ammassari,Raffaella Libertone,Mauro Zaccarelli,Valeria Ghisetti,Massimo Andreoni,Francesca Ceccherini-Silberstein,Stefano Bonora,G. Di Perri,Andrea Antinori,Carlo Federico Perno,M. M. Santoro

Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen

2016

To evaluate the maintenance of virological suppression (VS) in antiretroviral-treated HIV-1-suppressed patients switching to a tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) single-tablet regimen, by considering pre-existent resistance (pRes).

Keywords:

Virology
Tenofovir
Rilpivirine
Regimen
Emtricitabine
Biology
Reverse-transcriptase inhibitor
Proportional hazards model
Viremia
human immunodeficiency virus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations